The Claim
Cyclocreatine is transported into HEK293 cells and human blood-brain barrier model cells primarily through the creatine transporter SLC6A8, as evidenced by saturable uptake kinetics and reduced influx upon inhibition or knockdown of SLC6A8, indicating that cyclocreatine may act as a substrate for creatine transporter-mediated transport in cellular models relevant to brain delivery.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Cyclocreatine gets into brain-like cells in a lab mainly using a special doorway called the creatine transporter — when scientists block or remove this doorway, less cyclocreatine gets in, suggesting it relies on that path.
See the scientific wording
Cyclocreatine is transported into HEK293 cells and human blood-brain barrier model cells predominantly via the creatine transporter (SLC6A8), as demonstrated by saturable uptake kinetics and inhibition or knockdown of SLC6A8 reducing its influx, suggesting it may serve as a substrate for CRT-mediated transport in cellular models relevant to brain delivery.
What the research says
1 studyThe study shows that cyclocreatine gets into brain-relevant cells using the same gateway as creatine, and when that gateway is blocked or broken, less cyclocreatine gets in—just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.